All articles

Cardiff’s Onvansertib Shows To Be Helpful To RAS-Mutated Colorectal Cancer Patients

Merck’s $3 Billion Cost-Cutting Measure Is First Step For Intended Future Growth

FDA Alters Course On ELEVIDYS Shipping Pause For Ambulatory DMD Patients

CHMP Negative Opinion On ELEVIDYS Brings Further Woes For Sarepta And Its Partner Roche

Rocket Realigns Pipeline Towards Cardiovascular Targeting To Extend Cash Runway

Abivax’s Successful Phase 3 Ulcerative Colitis Trial Shows Obefazimod Differentiation

FDA Rejects Approval Of Replimune’s RP1 For Advanced Melanoma Patients, Type A Meeting Could Possibly Be Next Move

Third Patient Death That Dealt With LGMD Gene Therapy Puts Sarepta’s Pipeline At Risk

Scroll to Top